Judit Axmann

937 total citations · 1 hit paper
11 papers, 594 citations indexed

About

Judit Axmann is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Rheumatology. According to data from OpenAlex, Judit Axmann has authored 11 papers receiving a total of 594 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Physiology and 4 papers in Rheumatology. Recurrent topics in Judit Axmann's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (11 papers), Sarcoidosis and Beryllium Toxicity Research (7 papers) and Eosinophilic Disorders and Syndromes (4 papers). Judit Axmann is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (11 papers), Sarcoidosis and Beryllium Toxicity Research (7 papers) and Eosinophilic Disorders and Syndromes (4 papers). Judit Axmann collaborates with scholars based in United Kingdom, Switzerland and Germany. Judit Axmann's co-authors include Toby M. Maher, Michael Kreuter, María Molina‐Molina, Klaus-Uwe Kirchgaessler, Tamera J. Corte, Vincent Cottin, Aryeh Fischer, David J. Lederer, Frank Gilberg and Katerina Samara and has published in prestigious journals such as Thorax, The Lancet Respiratory Medicine and Respiratory Research.

In The Last Decade

Judit Axmann

11 papers receiving 586 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

2019 391 citations Toby M. Maher, Tamera J. Corte et al. The Lancet Respiratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Judit Axmann United Kingdom	6	566	252	104	75	68	11	594
Janelle Vu Pugashetti United States	10	391 0.7×	135 0.5×	74 0.7×	69 0.9×	27 0.4×	30	433
Helen E. Jo Australia	13	577 1.0×	240 1.0×	45 0.4×	55 0.7×	48 0.7×	31	606
Cathryn Lee United States	9	657 1.2×	230 0.9×	207 2.0×	176 2.3×	80 1.2×	13	700
Ada Vancheri Italy	12	308 0.5×	108 0.4×	118 1.1×	91 1.2×	27 0.4×	26	372
Cathryn T. Lee United States	11	338 0.6×	119 0.5×	59 0.6×	53 0.7×	22 0.3×	27	385
Mark Edwin United States	4	777 1.4×	244 1.0×	64 0.6×	104 1.4×	63 0.9×	7	853
Konstantinos Kagouridis Greece	11	443 0.8×	118 0.5×	31 0.3×	70 0.9×	19 0.3×	19	485
Laurens De Sadeleer Belgium	12	318 0.6×	135 0.5×	53 0.5×	51 0.7×	33 0.5×	32	406
Julia Wälscher Germany	11	260 0.5×	145 0.6×	22 0.2×	38 0.5×	33 0.5×	32	314
Chikatoshi Sugimoto Japan	13	403 0.7×	147 0.6×	13 0.1×	65 0.9×	48 0.7×	47	486

Countries citing papers authored by Judit Axmann

Since Specialization

Citations

This map shows the geographic impact of Judit Axmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judit Axmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judit Axmann more than expected).

Fields of papers citing papers by Judit Axmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judit Axmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judit Axmann. The network helps show where Judit Axmann may publish in the future.

Co-authorship network of co-authors of Judit Axmann

This figure shows the co-authorship network connecting the top 25 collaborators of Judit Axmann. A scholar is included among the top collaborators of Judit Axmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judit Axmann. Judit Axmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Maher, Toby M., Courtney Schiffman, Michael Kreuter, et al.. (2022). A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease. Respiratory Research. 23(1). 307–307. 17 indexed citations

Molina‐Molina, María, Michael Kreuter, Vincent Cottin, et al.. (2022). Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis. Frontiers in Medicine. 9. 897102–897102. 3 indexed citations

Kreuter, Michael, Toby M. Maher, Tamera J. Corte, et al.. (2021). Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use. Advances in Therapy. 39(2). 1081–1095. 5 indexed citations

Maher, Toby M., Tamera J. Corte, Michael Kreuter, et al.. (2020). Home Spirometry as a Primary Endpoint in Clinical Trials: Sensitivity Analyses of a Randomized Controlled Trial of Pirfenidone in Patients with Unclassifiable Interstitial Lung Disease (UILD). A2575–A2575. 3 indexed citations

Maher, Toby M., Tamera J. Corte, Aryeh Fischer, et al.. (2019). Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine. 8(2). 147–157. 391 indexed citations breakdown →

Maher, Toby M., Tamera J. Corte, Aryeh Fischer, et al.. (2019). Late Breaking Abstract - Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD). RCT1880–RCT1880. 2 indexed citations

Maher, Toby M., Jeffrey J. Swigris, Michael Kreuter, et al.. (2018). Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. Respiration. 96(6). 514–524. 56 indexed citations

Maher, Toby M., Tamera J. Corte, Aryeh Fischer, et al.. (2018). Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respiratory Research. 5(1). e000289–e000289. 43 indexed citations

Maher, Toby M., et al.. (2017). M19 Differences in patient and physician viewpoints of the management of idiopathic pulmonary fibrosis (ipf). HighWire Press Open Archive. A246.2–A249. 1 indexed citations

10.

Maher, Toby M., María Molina‐Molina, Anne‐Marie Russell, et al.. (2017). Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries. BMC Pulmonary Medicine. 17(1). 124–124. 70 indexed citations

11.

Maher, Toby M., María Molina‐Molina, Francesco Bonella, et al.. (2016). P161 Unmet needs in the treatment of idiopathic pulmonary fibrosis (IPF) – insights from patient chart review in five european countries. Thorax. 71(Suppl 3). A171–A172. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact